Literature DB >> 11857062

CDS1 and promoter single nucleotide polymorphisms of the CTLA-4 gene in human myasthenia gravis.

X B Wang1, M Kakoulidou, Q Qiu, R Giscombe, DeRen Huang, R Pirskanen, A K Lefvert.   

Abstract

The cytotoxic T lymphocyte associated protein 4 (CTLA-4) gene (Ctla-4) is a candidate gene for autoimmune disease. We here report results of two single nucleotide polymorphisms (SNPs) in the Ctla-4, a +49 A/G SNP in CDS1 and a C/T promoter SNP at position -318. There were no differences in these two SNPs between patients and healthy individuals. The frequency of allele G and genotype G/G at position +49 in CDS1 was increased in patients with thymoma when compared with patients with normal and hyperplastic thymic histopathology. Patients with the G/G genotype had signs of immune activation manifested as higher levels of serum IL-1beta and higher percentage of CD28(+) T lymphocytes. There was a strong linkage between the 86bp allele in the 3'-UTR and the A(+49) allele in CDS1. Our results suggest that the SNP at position +49 in CDS1 might be associated with the manifestations of MG.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11857062     DOI: 10.1038/sj.gene.6363816

Source DB:  PubMed          Journal:  Genes Immun        ISSN: 1466-4879            Impact factor:   2.676


  9 in total

1.  Induction of the CTLA-4 gene in human lymphocytes is dependent on NFAT binding the proximal promoter.

Authors:  Heather M Gibson; Carrie J Hedgcock; Barbara M Aufiero; Adam J Wilson; Mikehl S Hafner; George C Tsokos; Henry K Wong
Journal:  J Immunol       Date:  2007-09-15       Impact factor: 5.422

2.  [Association between CTLA-4 gene polymorphism and Henoch-Schönlein purpura in children].

Authors:  Hong-Hong Hou; Yan-Ping Huang; Li Liu; Gai-Tao He
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2017-03

3.  Association of -318 C/T and +49 A/G cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphisms with a clinical subset of Italian patients with systemic sclerosis.

Authors:  G Balbi; F Ferrera; M Rizzi; P Piccioli; A Morabito; L Cardamone; M Ghio; G L Palmisano; P Carrara; S Pedemonte; M Sessarego; M De Angioletti; R Notaro; F Indiveri; M P Pistillo
Journal:  Clin Exp Immunol       Date:  2007-04-25       Impact factor: 4.330

4.  Whole-genome analysis in Korean patients with autoimmune myasthenia gravis.

Authors:  Sang-Jun Na; Ji Hyun Lee; So Won Kim; Dae-Seong Kim; Eun Hee Shon; Hyung Jun Park; Ha Young Shin; Seung Min Kim; Young-Chul Choi
Journal:  Yonsei Med J       Date:  2014-04-01       Impact factor: 2.759

5.  High CTLA-4 expression correlates with poor prognosis in thymoma patients.

Authors:  Giorgio Santoni; Consuelo Amantini; Maria Beatrice Morelli; Daniele Tomassoni; Matteo Santoni; Oliviero Marinelli; Massimo Nabissi; Claudio Cardinali; Vittorio Paolucci; Mariangela Torniai; Silvia Rinaldi; Francesca Morgese; Giovanni Bernardini; Rossana Berardi
Journal:  Oncotarget       Date:  2018-03-30

6.  A Natural Variant of the Signaling Molecule Vav1 Enhances Susceptibility to Myasthenia Gravis and Influences the T Cell Receptor Repertoire.

Authors:  Isabelle Bernard; Antoine Sacquin; Sahar Kassem; Mehdi Benamar; Céline Colacios; Mylène Gador; Corine Pérals; Nicolas Fazilleau; Abdelhadi Saoudi
Journal:  Front Immunol       Date:  2018-10-25       Impact factor: 7.561

Review 7.  Insights Into the Host Contribution of Endocrine Associated Immune-Related Adverse Events to Immune Checkpoint Inhibition Therapy.

Authors:  Adrian Chye; India Allen; Megan Barnet; Deborah L Burnett
Journal:  Front Oncol       Date:  2022-07-14       Impact factor: 5.738

Review 8.  Recent advances in genetic predisposition of myasthenia gravis.

Authors:  Zoi Zagoriti; Manousos E Kambouris; George P Patrinos; Socrates J Tzartos; Konstantinos Poulas
Journal:  Biomed Res Int       Date:  2013-11-05       Impact factor: 3.411

9.  CTLA4 variants and haplotype contribute genetic susceptibility to myasthenia gravis in northern Chinese population.

Authors:  Liang Sun; Yunxiao Meng; Yanchen Xie; Hua Zhang; Zheng Zhang; Xiaoxia Wang; Bin Jiang; Wei Li; Yao Li; Ze Yang
Journal:  PLoS One       Date:  2014-07-08       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.